Ifebemtinib

• Description:

  Ifebemtinib (BI 853520) is an orally active and potent focal adhesion kinase (FAK) inhibitor (recombinant FAK IC50=1 nM) . Ifebemtinib shows anti-proliferative activity against cancer cells. Ifebemtinib inhibits FER Kinase and FES Kinase with IC50s of 900 nM and 1040 nM, respectively[1][2][3].

• Product Name Alternative:

  BI-853520; IN-10018

• UNSPSC:

  12352005

• Target:

  FAK

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bi-853520.html

• Concentration:

  10mM

• Purity:

  99.86

• Solubility:

  DMSO : 60 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=C(F)C=C(NC2=NC=C(C(F)(F)F)C(OC3=CC=CC4=C3C(N(C4)C)=O)=N2)C(OC)=C1)NC5CCN(CC5)C

• Molecular Formula:

  C28H28F4N6O4

• Molecular Weight:

  588.55

• References & Citations:

  [1]Stefanie Tiede, et al. The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis. 2018 Sep 20;7 (9) :73.|[2]Hirt UA, et al. Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis. 2018 Feb 23;7 (2) :21.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  [1227948-82-4]